Pancreatic Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Pancreatic cancer is a disease that is harmful to the pancreas. The fatal condition pancreatic adenocarcinoma is frequently found in an advanced stage. Near the head, body, or tail of the pancreas, a malignant tumor might be discovered. The 11th leading cause of cancer morbidity and the 7th leading cause of cancer-related death worldwide, respectively, are pancreatic cancer. The average lifetime incidence rate (ASR) is between 7 and 12. 7 per 100,000 people versus 2 in Europe. 2 for every 100,000 in Africa. Gemcitabine (Gem) has been the standard first-line therapy for PDAC for more than ten years. Furthermore, new treatment options for advanced PDAC may now be available as a result of recent advancements in maintenance therapy, particularly in this new era of long-lasting disease control made possible by first-line treatment regimens.

Description

Pancreatic cancer is a disease that is harmful to the pancreas. The fatal condition pancreatic adenocarcinoma is frequently found in an advanced stage. The head, body, or tail of the pancreas may be near a malignant tumor. Both glucagon and insulin, which help the body control blood sugar levels, are secreted by the pancreas, an organ. Pancreatic cancer is the fourth most prevalent disease in men and the fifth most common cancer in women. There are two subtypes of pancreatic cancer: exocrine and endocrine. Pancreatic ductal adenocarcinoma (PDAC) accounts for 90% of pancreatic tumors. Exocrine cancer is the most prevalent variety of pancreatic cancer. Exocrine pancreatic cancer affects the ducts in the pancreas that release the digestive juice.

Pancreatic Cancer (Epidemiology)

The 11th leading cause of cancer morbidity and the 7th leading cause of cancer-related death worldwide, respectively, are pancreatic cancer. The average lifetime incidence rate (ASR) is between 7 and 12. 7 per 100,000 people versus 2 in Europe. In Africa, there are two per 100,000. Between 0 and 1, the ASR varied by country. Between the ages of 15 and 24, 81 men out of every 100,000 in India. 3 per 100,000 men in the Republic of Moldova and in Latvia. In 2022, there will be about 62,210 new cases of pancreatic cancer diagnosed in the nation (32,970 in men and 29,240 in women), according to the American Cancer Society. From 2010 to 2019, the average annual increase in age-adjusted rates for new cases of pancreatic cancer was 0.5 %. In the absence of risk factors like familial pancreatic cancer and chronic pancreatitis, pancreatic cancer in individuals under the age of 45 is uncommon. After age 50, the risk of developing pancreatic cancer rises linearly with age. Black people are typically diagnosed at age 65, compared to white people's average age of 69 at diagnosis. The median age at diagnosis for both sexes has decreased to 63 years of age, according to some single-institution data from significant cancer centers. Despite only accounting for about 3% of all cancer cases in the nation, pancreatic cancer is the fourth most common cause of cancer-related death in both men and women, and it is also the cause of 8% of cancer-related deaths overall. The American Cancer Society predicts that 47,050 Americans (24,640 men and 22,410 women) will die of pancreatic cancer in the US in 2020. Between 2008 and 2017, Black people's annual death rate from pancreatic cancer increased a minuscule 0.5%. The decline in Whites was minimal (by 0.4% annually).

Pancreatic Cancer -Current Market Size & Forecast Trends

The market for pancreatic cancer treatment is projected to experience substantial growth, with estimates indicating a current value of approximately USD 2.86 billion in 2024. This market is expected to reach around USD 10.25 billion by 2034, reflecting a compound annual growth rate (CAGR) of 13.62% during this period. The growth is driven by the rising incidence of pancreatic cancer, advancements in treatment options such as chemotherapy and targeted therapies, and increased investment in research and development. The North American market is anticipated to dominate due to its advanced healthcare infrastructure and ongoing clinical trials. Overall, the pancreatic cancer market is well-positioned for significant expansion through 2035, supported by innovative therapeutic strategies and heightened awareness of the disease.

Gemcitabine (Gem) has been the mainstay of first-line therapy for PDAC for more than ten years. Attempts to increase the effectiveness of single-agent GEMs by combining them with other cytotoxic/molecularly targeted medications or by modifying their pharmacokinetics have generally failed to produce desired outcomes. Systemic therapy for advanced PDAC has recently made some progress. Several chemotherapies have demonstrated promising outcomes when compared to single-agent stones: regimens like PEFG-PEXG-PDXG and GTX have significant potential benefits in terms of survival and/or disease control, but occasionally at the expense of poor tolerability. The first phase III study, PRODIGE 4/ACCORD 11, showed a distinct advantage of multiple FOLFIRINOX chemotherapy regimens; however, the less favorable safety profile and profile of the enrolled population restrict the use of FOLFIRINOX in young, healthy patients with PDAC. To circumvent drug resistance by encasing pancreatic cancer cells in a synthetic matrix, paclitaxel has been conjugated with nanoparticles. The combination of nab-paclitaxel and Gem demonstrated a statistically and clinically significant survival advantage over single beads, regardless of whether these were the primary mechanisms of action. Additionally, there were significant improvements in all secondary endpoints. Furthermore, new treatment options for advanced PDAC may now be available as a result of recent advancements in maintenance therapy, particularly in this new era of long-lasting disease control made possible by first-line treatment regimens that are extremely effective.

Report Highlights

Pancreatic Cancer - Current Market Trends

Pancreatic Cancer - Current & Forecasted Cases across the G8 Countries

Pancreatic Cancer - Market Opportunities and Sales Potential for Agents

Pancreatic Cancer - Patient-based Market Forecast to 2035

Pancreatic Cancer - Untapped Business Opportunities

Pancreatic Cancer - Product Positioning Vis-a-vis Competitors' Products

Pancreatic Cancer - KOLs Insight